18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer

30 October - 2 November 2003, Bethesda, Maryland, USA

Francesco M. Marincola, Ena Wang, Michael B. Atkins

Research output: Contribution to journalArticle

Abstract

The 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc) was held at the Hyatt Regency, Bethesda, MD, close to the National Institutes of Health (NIH) campus. The meeting was organised on behalf of the society by Neil Berinstein from Aventis Pasteur, Toronto, Canada, Janice P Dutcher from Our Lady of Mercy Medical Center, Bronx, NY and Francesco M Marincola from the NIH, Bethesda, MD. The 2003 meeting included 57 oral presentations and > 100 poster presentations. There were > 800 registrants to the Annual Meeting and the multiple satellite symposia. The iSBTc, formerly the Society of Biological Therapy (SBT), was founded by R Oldham in 1984. Its membership has been rapidly growing of late, with > 500 members at present. The purpose of the iSBTc is to bring together those diverse individuals actively investigating biologic agents and biological response modifiers in the treatment of cancer, including clinicians and basic scientists from industry, government and academia. The President of the Society is Dr Michael B Atkins from Beth Israel Deaconess Medical Center, Boston, MA and the Vice President is Ulrich Keilholz from UKBF, Free University Berlin, Germany.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume4
Issue number1
DOIs
Publication statusPublished - Jan 2004
Externally publishedYes

Fingerprint

Biological Therapy
National Institutes of Health (U.S.)
Health
Immunologic Factors
Biological Factors
Posters
Neoplasms
Satellites
Berlin
Israel
Canada
Germany
Industry
Therapeutics

Keywords

  • Antiangiogenesis
  • Biotherapy
  • Cancer
  • Cytokines
  • Dendritic cells
  • EBV
  • Genomics
  • IFN
  • IL-12
  • IL-2
  • Immunotherapy
  • Monoclonal antibodies
  • MRI
  • Natural killer cells
  • Polymorphism
  • Vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer : 30 October - 2 November 2003, Bethesda, Maryland, USA. / Marincola, Francesco M.; Wang, Ena; Atkins, Michael B.

In: Expert Opinion on Biological Therapy, Vol. 4, No. 1, 01.2004, p. 107-114.

Research output: Contribution to journalArticle

@article{b5d7471206984383985381e41381f444,
title = "18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer: 30 October - 2 November 2003, Bethesda, Maryland, USA",
abstract = "The 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc) was held at the Hyatt Regency, Bethesda, MD, close to the National Institutes of Health (NIH) campus. The meeting was organised on behalf of the society by Neil Berinstein from Aventis Pasteur, Toronto, Canada, Janice P Dutcher from Our Lady of Mercy Medical Center, Bronx, NY and Francesco M Marincola from the NIH, Bethesda, MD. The 2003 meeting included 57 oral presentations and > 100 poster presentations. There were > 800 registrants to the Annual Meeting and the multiple satellite symposia. The iSBTc, formerly the Society of Biological Therapy (SBT), was founded by R Oldham in 1984. Its membership has been rapidly growing of late, with > 500 members at present. The purpose of the iSBTc is to bring together those diverse individuals actively investigating biologic agents and biological response modifiers in the treatment of cancer, including clinicians and basic scientists from industry, government and academia. The President of the Society is Dr Michael B Atkins from Beth Israel Deaconess Medical Center, Boston, MA and the Vice President is Ulrich Keilholz from UKBF, Free University Berlin, Germany.",
keywords = "Antiangiogenesis, Biotherapy, Cancer, Cytokines, Dendritic cells, EBV, Genomics, IFN, IL-12, IL-2, Immunotherapy, Monoclonal antibodies, MRI, Natural killer cells, Polymorphism, Vaccines",
author = "Marincola, {Francesco M.} and Ena Wang and Atkins, {Michael B.}",
year = "2004",
month = "1",
doi = "10.1517/14712598.4.1.107",
language = "English",
volume = "4",
pages = "107--114",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer

T2 - 30 October - 2 November 2003, Bethesda, Maryland, USA

AU - Marincola, Francesco M.

AU - Wang, Ena

AU - Atkins, Michael B.

PY - 2004/1

Y1 - 2004/1

N2 - The 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc) was held at the Hyatt Regency, Bethesda, MD, close to the National Institutes of Health (NIH) campus. The meeting was organised on behalf of the society by Neil Berinstein from Aventis Pasteur, Toronto, Canada, Janice P Dutcher from Our Lady of Mercy Medical Center, Bronx, NY and Francesco M Marincola from the NIH, Bethesda, MD. The 2003 meeting included 57 oral presentations and > 100 poster presentations. There were > 800 registrants to the Annual Meeting and the multiple satellite symposia. The iSBTc, formerly the Society of Biological Therapy (SBT), was founded by R Oldham in 1984. Its membership has been rapidly growing of late, with > 500 members at present. The purpose of the iSBTc is to bring together those diverse individuals actively investigating biologic agents and biological response modifiers in the treatment of cancer, including clinicians and basic scientists from industry, government and academia. The President of the Society is Dr Michael B Atkins from Beth Israel Deaconess Medical Center, Boston, MA and the Vice President is Ulrich Keilholz from UKBF, Free University Berlin, Germany.

AB - The 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc) was held at the Hyatt Regency, Bethesda, MD, close to the National Institutes of Health (NIH) campus. The meeting was organised on behalf of the society by Neil Berinstein from Aventis Pasteur, Toronto, Canada, Janice P Dutcher from Our Lady of Mercy Medical Center, Bronx, NY and Francesco M Marincola from the NIH, Bethesda, MD. The 2003 meeting included 57 oral presentations and > 100 poster presentations. There were > 800 registrants to the Annual Meeting and the multiple satellite symposia. The iSBTc, formerly the Society of Biological Therapy (SBT), was founded by R Oldham in 1984. Its membership has been rapidly growing of late, with > 500 members at present. The purpose of the iSBTc is to bring together those diverse individuals actively investigating biologic agents and biological response modifiers in the treatment of cancer, including clinicians and basic scientists from industry, government and academia. The President of the Society is Dr Michael B Atkins from Beth Israel Deaconess Medical Center, Boston, MA and the Vice President is Ulrich Keilholz from UKBF, Free University Berlin, Germany.

KW - Antiangiogenesis

KW - Biotherapy

KW - Cancer

KW - Cytokines

KW - Dendritic cells

KW - EBV

KW - Genomics

KW - IFN

KW - IL-12

KW - IL-2

KW - Immunotherapy

KW - Monoclonal antibodies

KW - MRI

KW - Natural killer cells

KW - Polymorphism

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0346095599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346095599&partnerID=8YFLogxK

U2 - 10.1517/14712598.4.1.107

DO - 10.1517/14712598.4.1.107

M3 - Article

VL - 4

SP - 107

EP - 114

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -